In this issue, Khalilieh et al. [1] report the result of a ''Thorough QT'' (TQT) study on doravirine, a novel human immunodeficiency virus-1 non-nucleoside reverse transcriptase inhibitor. The implications of these findings go beyond the results per se, which confirm the good tolerability of the agent for the pro-arrhythmic profile. The TQT study was set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E14 guideline to assess the pro-arrhythmic potential of drugs during their clinical development, in response to a series of case reports published between the 1980s and 1990s showing an unexpected occurrence of sudden deaths in association with several non-cardiovascular drugs in the post-marketing setting. Some of these drugs, which were mostly prescribed for the treatment of relatively benign indications, were withdrawn from the market because of documented arrhythmogenicity [2] . Later, a relationship emerged between episodes of sudden death and the occurrence of a polymorphic form of ventricular tachycardia (i.e., torsade de pointes, TdP), which is preceded by prolongation of the QT interval, as measured on the electrocardiogram (ECG) surface. Frequently, QT prolongation is the result of drug-induced blockade of the hERG K ? channels, which delays ventricular repolarization [3] . This led to the consideration that QT prolongation was the principal predictor of torsadogenic risk, or even a surrogate marker of TdP and in turn prompted regulators to develop a strategy based on TQT studies. Since the implementation of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E14 guideline, more than 400 TQT studies have been conducted, although they are mostly not published, especially those with negative results [4] .
Although it is undoubtedly useful to have pre-marketing clinical data on the effect of drugs on the QT interval, the TQT study raised debate and was criticized for uncertain actual cost effectiveness and (over)reliance on an imperfect marker [5] . In addition, from a technical point of view, measuring QT interval length is not a straightforward procedure because several factors can affect the final result: (1) the ECG lead used for the QT assessment (single or multiple; in the case of multiple leads, we have to choose between the median, maximum, or average QT); (2) the method adopted to determine the end of the T wave [6] ; and (3) manual or automated measurement. Khalilieh et al. [1] probably adopted the best approach for QT evaluation, with high-resolution digital 12-lead ECGs extracted from a continuous 12-lead Holter coupled with automated QT analysis verified by a human operator [7] . However, it is challenging to apply a similar approach in clinical settings. The standard 'real-world' practice of corrected QT interval (QTc) assessment is based on a rest 12-lead paper ECG, without human confirmation. Moreover, drug administration is unfrequently considered to schedule the ECG while an off-drug baseline ECG is only seldom available. The optimal QTc duration for a heart rate represents another debated issue. Several methods have been proposed beyond Bazett's formula [7] , but they all assume that the relationship between QT and heart rate is fixed for individuals with different cardiovascular profiles, despite recent data showing that the QT/heart rate relationship is stable within an individual but varies significantly between individuals [8, 9] . For the same reason, a different approach has been developed to exploit the availability of baseline ECG data: the adoption of patient/population-specific QT/RR plots before and after administration of placebo and the active compound [10] . This approach, albeit technically demanding, seems to provide the best results for discriminating between placebo and compounds known to prolong QTc [11] . Notably, this method increases the specificity in a QTc assessment to prevent a failing TQT study because of an over-correction, as reported for quetiapine [12] . However, are we sure that the adoption of a more personalized QTc will provide more relevant results?
It is known that several physiological factors may affect the QT interval duration beyond heart rate: sex, age, sympatho-vagal balance, and even meal intake [13, 14] . In particular, we have limited and conflicting data on the influence of ethnicity/race on QTc prolongation [15, 16] and even less information on the risk of drug-induced TdP. However, TQT studies are frequently conducted in non-Caucasian populations, largely as a means of minimizing costs for the conduct of the study. For this reason, extrapolation of the results obtained in a limited population of a specific ethnicity to the general population, including other ethnicities warrants caution. In this regard, the prevalence of White non-Hispanic/Latino subjects enrolled in the study of Khalilieh et al. [1] was around 10% with 75% Black/African American, thus highlighting the uncertainty about generalization of the results. This was, at least partially, mitigated by the choice to provide both a population-specific QTc analysis and an analysis based on the more standard Fridericia's QT correction. Although this approach enhances the possibility of comparing results with literature data and clinical practice, it should be emphasized that subjects enrolled in TQT studies differ from real-world patients receiving polypharmacy [17] and having co-morbidities, which act as modifiers of drug effects and increase the likelihood of TdP [18, 19] .
For all these reasons, the results of a TQT study cannot be viewed as having a 'pass or fail' categorization, but should instead guide a proactive ECG monitoring strategy in future drug development, including the post-marketing phase, to limit the detrimental effects of false-negative/positive results [20] . This mushrooming of TQT studies has therefore created a conundrum for clinical pharmacology journals and the question arises as to whether and how editors should publish relevant results in the era of transparency and the full release of datasets. Channeling TQT studies with specific scientific merit to the open access option has been proposed or, more controversially, data storage in a structured open-access database has been advocated [21] .
To overcome these issues, two alternative strategies have been proposed [5] to replace the TQT study: (1) incorporating robust ECG monitoring during phase I single and multiple ascending doses (studies offering the opportunity to assess the concentration-effect relationship for QT changes at a wide range of dosages [22] ) and (2) the comprehensive in-vitro pro-arrhythmia assay, which calls for a paradigm shift in drug development through the use of three pre-clinical approaches [23] . Both proposals, albeit promising, are neither fully validated by the scientific community nor accepted by regulators. A proposed desirable strategy would be to implement a stepwise approach from pre-clinical studies to identify molecules for which a TQT study is not required and discriminate (when a TQT study is warranted because of inconclusive/ambiguous pre-clinical data) drugs with TdP liability (likely to result in an actual pro-arrhythmic risk in humans) from those with only QT liability (unlikely to be arrhythmogenic). The latter case (i.e., risk stratification) is challenging to achieve, but it would be of great value for clinicians (Fig. 1) . For well-established drugs (on the market for decades), prescribers may easily consult the website [24] , where Woosley and colleagues are constantly updating the categorization of drugs on the basis of torsadogenic potential and those to be avoided in patients with long QT syndrome. A future highly interesting step is to help identify safe therapeutic alternatives when the increase in TdP risk should be minimized in specific cases. [25] .
Irrespective of the approach used in premarketing study, it is essential to monitor the arrhythmogenic potential of drugs in a real-world setting. The recently concluded project 'ARITMO' [26, 27] , funded by the European Commission at the request of the European Medicines Agency, assessed the TdP liability of antimicrobials, antipsychotics, and antihistamine drugs by analyzing (systematic literature review), generating, and integrating heterogeneous evidence from spontaneous adverse drug reaction reporting systems, healthcare databases, observational on-field studies, in-silico simulations, and genetic data, with the ultimate goal to score the drug-specific arrhythmogenic potential. In the era of big data, evidence integration from pre-and post-marketing settings is an extraordinary opportunity for a better assessment of the drug/benefit-risk assessment. Pharmacoepidemiological studies conducted using the ARITMO database network highlighted the importance of considering the heterogeneous spectrum of clinical entities strictly related to TdP, from the most severe outcomes such as sudden cardiac death and ventricular arrhythmias (albeit less frequently associated with drug-induced QT prolongation), to asymptomatic QT prolongation (more frequently but hardly to be observed in clinical practice) to study the association of drugs with arrhythmias [28] [29] [30] .
The real challenge is represented by the timely identification of arrhythmogenic potential for newly marketed molecular entities entering the market with accelerated approval. The uncertainty on the safety profile of these drugs makes the post-marketing phase essential to define the real risk-benefit profile, also in relation to the risk of cardiac arrhythmias. In this context, spontaneous reporting systems such as the US Food and Drug Adverse Adverse Event Reporting System are essential sources for the timely detection of rare drug-induced toxicities such as TdP, for monitoring the need for risk-minimization activities, and for providing preliminary clues for prescribers and regulators [31] , and may benefit from the combination of realworld data from large distributed database networks [32] .
In conclusion, the current regulatory paradigm based on TQT studies provides useful hints for both research and clinical purposes, but presents several caveats that heavily affect the generalization and implications of QT data for both purposes. We need to balance the choice of 'almost perfect' methods for ECG assessment, including QTc, with the transferability of the obtained results to clinical settings. An integrated approach including both pre-clinical findings and post-marketing data is the most promising strategy to support the assessment and management of proarrhythmic risk beyond QTc prolongation, independently of the adopted heart rate correction formula.
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Conflict of interest Igor Diemberger, Emanuel Raschi, and Gianluca Trifirò have no conflicts of interest directly relevant to the contents of this article. Fig. 1 Traditional vs. integrated approach to proarrhythmic risk evaluation during novel drug development. The traditional approach is based on the thorough QT (TQT) study, which ideally should be performed in phase I to allow the settlement of specific electrocardiogram (ECG) studies (seldom performed in real practice) in phase III on a broader population more similar to the final user. However, in several cases, TQT studies are performed in phase II-III. ADR-RS adverse drug reaction reporting systems, CIPA comprehensive invitro pro-arrhythmia assay
